Be the first to receive the latest news and insights specific to the pharma and life sciences sector by using the below form.
Pharma and life sciences businesses, understandably, tend to focus on the science and development of ideas and the groundbreaking therapies this might lead to. However, leveraging all available resources, such as allowances and tax reliefs, is also something these companies should be considering. While leading pharmaceutical companies have large departments dedicated to this, smaller businesses in...
Pharma and life sciences companies should act now to prevent impact on drug production capabilities and business viability.
At a pivotal time in the political landscape, the Chancellor revealed his Spring Budget and continued his theme of long-term growth. Amidst jeering and numerous interventions from the deputy speaker, his plans presented more than just tinkering around the edges.
As companies face increasing scrutiny and an aggressive drive to criminalise corporate misconduct, there has been a marked increase in firms conducting internal investigations. Nigel Layton, our Head of Investigations and Global Head of Pharma & Life Sciences, explains the key components of a successful internal investigation.
Nigel Layton, our Global Head of Pharma & Life Sciences and UK Head of Investigations, gives his insight on anti-bribery and corruption within the pharma and life sciences sector.
The pandemic demonstrated beyond any reasonable doubt that the life sciences, pharma and healthcare sectors play a critical role in society. Developing, testing and manufacturing vaccines was key to beating Covid-19.
Mazars is committed to supporting the pharma and life sciences sector; helping companies to navigate disruption, embrace innovation and grow with confidence. That’s why we recently partnered with FT Live for their Global Pharma and Biotech Summit - bringing the industry together to explore the latest trends, share top expertise and drive growth.
05/10/2023. Tarifa Simpson, our Healthcare & Life Sciences Co-Lead and Due Diligence Partner, gives her views on the current deals environment within the healthcare and life sciences sector.
Acting on the principles embodied in ESG (environmental, social and governance) is fraught with difficulty.
06/02/23. Employing apprentices is nothing new. It has been in place for hundreds of years, in various forms. However, one of the biggest changes in a generation took place in April 2017 as the Apprenticeship Levy was introduced to give employers more control over how they govern and control training costs.
The cost of living and energy crisis as well as a continued potential discontent continues to loom large. Despite recent Government measures.
Life sciences organisations currently have great potential to thrive in the UK however, they are also facing significant challenges which, if not managed correctly, will limit this opportunity. Hear from industry experts to learn what boards must consider to successfully govern in this post-Covid era.
Clearly, Jeremy Hunt was wanting to champion the importance of the life sciences sector to the UK’s economy. It was probably singled out more times in his speech than any other sector and a few of the reforms announced today go some way to address criticism around the competitiveness of the UK corporation tax system for this sector, particularly in advance of the rise of the headline rate to 25% from...
Amidst uncertainty in the wider economy, life sciences companies need to be better prepared to de-risk investment decisions and complete transactions. Whilst this may have a short-term impact on M&A activity, we expect deal volumes to recover by the end of the year.
A roundup of the latest trends and developments in corporate reporting for the life sciences and pharmaceutical industry.
Why companies within the Pharmaceutical and Life Sciences sector need to be aware of the tax implications before entering into collaborative arrangements.
The tax implications arising from the paradigm shift to remote working and virtual collaboration this past year in the pharmaceutical and life science sector are complex on different levels.
Bringing new drugs to market is risky, lengthy, complex, and costly, so pharmaceutical companies are rationalising their major R&D centres worldwide to collaborate with partners. This is where international R&D tax incentives play their part.
Despite increased enforcement of anti-graft legislation, such as the US Foreign Corrupt Practices Act (“FCPA”) and China’s own commercial bribery laws, fraud and corruption remain rife across many industries in China.
With specialist pharma and life sciences hubs in the UK, USA, Switzerland, France, Germany and Ireland, our dedicated Global Pharma & Life Sciences team combines global experience and industry expertise.
Helping life sciences companies have sustainable growth in an innovative manner to deliver better health outcomes for society
This website uses cookies.
Some of these cookies are necessary, while others help us analyse our traffic, serve advertising and deliver customised experiences for you.
For more information on the cookies we use, please refer to our Privacy Policy.
This website cannot function properly without these cookies.
Analytical cookies help us enhance our website by collecting information on its usage.
We use marketing cookies to increase the relevancy of our advertising campaigns.